We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Specificity Improved for Urinary Antigen Testing

By LabMedica International staff writers
Posted on 23 May 2017
Print article
Image: The Cryptococcal Antigen Lateral Flow Assay (CrAg LFA) Immy test (Photo courtesy of Immuno-Mycologics).
Image: The Cryptococcal Antigen Lateral Flow Assay (CrAg LFA) Immy test (Photo courtesy of Immuno-Mycologics).
The cryptococcal antigen lateral flow assay (CrAg LFA) Immy test is standardized for a fast screening point-of-care test for cryptococcosis, detecting cryptococcal antigen in serum and cerebrospinal fluid (CSF).

A delay in laboratory diagnosis is related to sequelae and death and therefore early diagnosis is the key to decrease the high lethality rate due to cryptococcosis. Urine screening would be ideal as a noninvasive approach, but previous studies have shown that fresh urine present false positive results.

Scientists at the National Institute of Infectious Diseases Evandro Chagas performed a prospective cohort study from April 2014 to April 2015 on 77 volunteers: 53 HIV-positive (CD4+ T cell less than 200 cells/mm3) patients, 18 healthy individuals (negative controls), and six HIV-positive patients with active proven cryptococcosis (positive controls). Healthy individuals were included as a negative control and patients presenting proven cryptococcosis as a positive control.

Cryptococcal antigen testing was performed in blood serum and urine from each volunteer using the CrAg LFA Immy test. Each fresh urine sample was tested under two conditions: unheated (untreated) and heated (treated) by five minutes incubation at 100 °C. Clinical specimens such as blood, CSF, and urine were subsequently cultivated to investigate cryptococcal infection. The CrAg LFA in serum samples was considered as the gold standard.

The investigators reported that 24/53 HIV-positive volunteers had a CrAg LFA–positive profile (42.3%) when untreated fresh urine was tested. When heated, only eight samples were positive (15%), presenting 100% of agreement with the positive results obtained from serum samples submitted to CrAg LFA Immy assay. Out of those eight positive patients, five had proven cryptococcosis (positive culture for Cryptococcus neoformans in CSF and/or blood culture) and three patients had cryptococcal antigenemia (negative for Cryptococcus in blood and CSF cultures). The untreated fresh urine has shown 16 false positive results (30.2%). After treatment, those urine samples were negative, as confirmed by negative results in the serum.

The authors concluded that heating of urine prior testing dramatically improved the test’s specificity without compromising the test’s sensitivity. This crucial step has dramatically increased the specificity without compromising test sensitivity, with two additional advantages: no need of enzymatic treatment or sample dilution. The study was published on the journal Public Library of Science Neglected Tropical Diseases.

New
Gold Member
Veterinary Hematology Analyzer
Exigo H400
Gold Member
Troponin T QC
Troponin T Quality Control
New
MTHFR Mutation Test
REALQUALITY THROMBO MTHFR
New
Refrigerated Centrifuge
CAPPRondo Refrigerated Centrifuge

Print article

Channels

Molecular Diagnostics

view channel
Image: A coronal MRI section shows a high-intensity focused ultrasound lesion in the left thalamus of the brain (Photo courtesy of UT Southwestern Medical Center)

Newly Identified Stroke Biomarkers Pave Way for Blood Tests to Quickly Diagnose Brain Injuries

Each year, nearly 800,000 individuals in the U.S. experience a stroke, which occurs when blood flow to specific areas of the brain is insufficient, causing brain cells to die due to a lack of oxygen.... Read more

Pathology

view channel
Image: As tumor cells flow through these microfluidic chambers, they are subjected to increasing shear stress and sorted based on their adhesion strength (Photo courtesy of UC San Diego)

Microfluidic Device Assesses Stickiness of Tumor Cells to Predict Cancer Spread

Ductal carcinoma in situ (DCIS), a type of early-stage breast cancer, is often referred to as stage zero breast cancer. In many cases, it remains harmless and does not spread beyond the milk ducts where... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.